Madrigal Pharmaceuticals, Inc.
MDGL
Rank in Stocks
#2022
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Share Price
$446.50
Market Cap
$10.32B
Change (1 day)
-0.72%
Change (1 year)
1.73%
Country
US
Trade Madrigal Pharmaceuticals, Inc. (MDGL)
Category
Healthcare
P/E ratio for Madrigal Pharmaceuticals, Inc. (MDGL)
P/E ratio as of October 2026 TTM: -35.69
According to Madrigal Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -35.69. At the end of 2023 the company had a P/E ratio of -11.57.
P/E ratio history for Madrigal Pharmaceuticals, Inc. from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -35.69 | 153.28% |
| 2024 | -14.09 | 21.75% |
| 2023 | -11.57 | -31.28% |
| 2022 | -16.84 | 190.68% |
| 2021 | -5.79 | -31.77% |
| 2020 | -8.49 | -49.18% |
| 2019 | -16.71 | -67.13% |
| 2018 | -50.83 | 40.90% |
| 2017 | -36.08 | 1,127.55% |
| 2016 | -2.94 | 860.14% |
| 2015 | -0.31 | -89.90% |
| 2014 | -3.03 | -26.54% |
| 2013 | -4.12 | -51.67% |
| 2012 | -8.53 | 83.48% |
| 2011 | -4.65 | -29.45% |
| 2010 | -6.59 | -404.03% |
| 2009 | 2.17 | -197.26% |
| 2008 | -2.23 | -34.93% |
| 2007 | -3.43 | -3.06% |
| 2006 | -3.53 | 20.31% |
| 2005 | -2.94 | -20.64% |
| 2004 | -3.70 | -48.05% |
| 2003 | -7.13 | 135.36% |
| 2002 | -3.03 | -95.67% |
| 2001 | -69.92 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -180.65% |
US
|
|
| -28.36 | -20.54% |
US
|
|
| -24.57 | -31.16% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -184.99% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.